A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice

Psychoneuroendocrinology
Rai Khalid FarooqVincent Camus

Abstract

A polymorphism in the P2RX7 gene that encodes for the P2X7 ionotropic ATP-gated receptor (P2X7R) protein has been shown to be associated with an increased risk for developing depressive illnesses. However, the role of P2X7R in depression is still unclear. To better understand the role of P2X7R and its subsequent impact on microglial activation, we compared the effect of the P2X7R antagonist Brilliant Blue G (BBG) with that of fluoxetine in an unpredictable chronic mild stress (UCMS) model of depression in mice. Our results indicate that BBG (50 mg/kg body weight in 0.9% NaCl, 10 ml/kg/day) successfully reversed the degradation of coat states and nest-building scores induced by exposure to UCMS, similar to the conventional antidepressant fluoxetine (15 mg/kg body weight in 0.9% NaCl, 10 ml/kg/day). BBG also reversed the UCMS-induced microglial activation in cortical and hippocampal regions and the basal nuclei of mouse brains and corrected the UCMS-induced hypothalamo-pituitary-adrenal (HPA) axis dysregulation. In contrast to fluoxetine, however, BBG treatment did not increase the density of doublecortin-positive cells in the dentate gyrus, indicating that BBG had no impact on hippocampal neurogenesis. These results suggest that...Continue Reading

Citations

Mar 21, 2019·American Journal of Physiology. Lung Cellular and Molecular Physiology·Qing-Chun LiZhen-Bo Su
Jun 9, 2019·International Journal of Molecular Sciences·Deidiane Elisa RibeiroSâmia Joca
Jan 28, 2020·The European Journal of Neuroscience·Mélanie KremerIpek Yalcin
Nov 22, 2018·Frontiers in Cellular Neuroscience·Lijuan ZhangZili You
Jan 22, 2020·Neural Regeneration Research·Lin-Hua Jiang, Sébastien Roger
Feb 23, 2020·Frontiers in Molecular Neuroscience·Peter IllesYong Tang
Aug 28, 2020·Frontiers in Molecular Neuroscience·Roberta AndrejewHenning Ulrich
Mar 10, 2020·The European Journal of Neuroscience·Romain TroubatVincent Camus
Dec 18, 2020·Molecular Psychiatry·Deidiane Elisa RibeiroHenning Ulrich
Dec 11, 2020·Mediators of Inflammation·Shu-Lin ShaoShu-Ming Huang
Feb 16, 2021·Neurochemistry International·Katherine PicardMarie-Ève Tremblay
Feb 21, 2021·Brain, Behavior, and Immunity·Romain TroubatVincent Camus
Feb 20, 2021·Pharmacology & Therapeutics·Aleksandra SzopaPiotr Wlaź
May 1, 2021·Frontiers in Pharmacology·Roberto F AlmeidaElaine Elisabetsky
Jun 9, 2021·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Gabriele Cheiran PereiraGuilherme Vargas Bochi
Jul 17, 2020·CNS & Neurological Disorders Drug Targets·Alice Barros Câmara, Igor Augusto Brandão
Jul 20, 2021·European Archives of Psychiatry and Clinical Neuroscience·Iven-Alex von Muecke-HeimJan M Deussing
Jul 25, 2021·International Journal of Molecular Sciences·Julia LeschikAntonietta Gentile
Nov 24, 2021·Frontiers of Medicine·Yang LiaoZengqiang Yuan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.